RFI - Medical Countermeasures for the Treatment of Drug-Resistant Fungal Infections RFI-MCM-TDRFI-BARDA-2026
Summary
AI-generated · May 22, 2026BARDA/ASPR at HHS is seeking information from current and prospective antifungal development partners about their qualifications, experience, and capabilities to inform planning for potential future acquisitions and programs addressing medical countermeasures for drug-resistant fungal infections. Respondents will include both Small Businesses and Other-Than-Small Businesses, and the information collected will help BARDA strengthen its understanding of the current and future marketplace to guide potential initiatives.
The Center for the Biomedical Advanced Research and Development Authority (BARDA), Administration for Strategic Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS), is issuing this Request for Information (RFI) to collect feedback from current and prospective antifungal development partners. Information obtained from this RFI will serve as continued planning for potential future acquisitions and programs. The information collected in response to this RFI is intended to strengthen BARDA s understanding of the current and future marketplace. This notice seeks information from Other than Small Businesses (OTSB) and Small Businesses (SB) regarding their qualifications, experience, and capabilities.
From Sources Sought posted on May 21, 2026Notice history
1-
Sources Sought LATEST Posted May 21, 2026
Details
Award Information
Not yet awarded
Contacts
Agency
Place of Performance
USA